Health
Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals – News-Medical.Net
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe…
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate the safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.
Opaganib potentially minimizes the likelihood of resistance due to viral mutations by targeting a human cell component involved…
-
Noosa News18 hours agoPill checking to resume in Queensland months after government axed funding
-
Business21 hours agoWhy Austal, Boss Energy, Harvey Norman, and NextDC shares are charging higher today
-
Business22 hours agoASX shares are expensive. Here’s why you should be buying anyway
-
Noosa News16 hours agoQueensland girl Millie’s fight for life after magnets tore through her bowel